Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar-Apr;3(2):167-74.
doi: 10.1016/j.jaip.2015.01.013.

Biologic therapies targeting eosinophils: current status and future prospects

Fanny Legrand  1 , Amy D Klion  2
Affiliations
Review

Biologic therapies targeting eosinophils: current status and future prospects

Fanny Legrand et al. J Allergy Clin Immunol Pract. 2015 Mar-Apr.

Abstract

The recent explosion in the number of biologic therapies in clinical development for the treatment of eosinophilic disorders is unprecedented. As these agents become available for clinical use, the selection of the most appropriate agent for a given patient will become increasingly complicated. The aims of this review were 2-fold: (1) to present the lessons learned from clinical trials using the first generation of eosinophil-targeted biologics (anti-IL-5 antibodies) and (2) to discuss the advantages and potential limitations of currently available and novel targeted therapies to treat eosinophilic disorders.

Keywords: Asthma; Benralizumab; Eosinophilic gastrointestinal disorders; Hypereosinophilic syndrome; Mepolizumab; Reslizumab; mAb.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Mechanism of action of biologic therapies for treatment of EAD. Agents targeting eosinophil surface receptors are shown in panel A and mediators associated with eosinophilic inflammation in vivo in panel B. MC = mast cell, baso = basophil.
See this image and copyright information in PMC

References

    1. Bochner BS, Book W, Busse WW, Butterfield J, Furuta GT, Gleich GJ, et al. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol. 2012;130:587–96. - PMC - PubMed
    1. Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract. 2014;2:671–80. - PubMed
    1. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–25. e3. - PMC - PubMed
    1. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958–72. - PubMed
    1. Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, et al. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol. 2012;130:563–71. - PMC - PubMed

Publication types